A Phase 1 interventional study of RXIM002 in Immune Thrombocytopenia (ITP), sponsored by RiboX Therapeutics Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by RiboX Therapeutics Ltd. · Phase 1, Interventional, and Treatment
The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.
Exclusion Criteria:
Open-label, single arm with 3 dose-level cohorts of RXIM002
Biological: RXIM002
Targeted lipid nanoparticle (tLNP)-delivered circular ribonucleic acid (circRNA) encoding an anti-human CD19 chimeric antigen receptor (CAR)
Incidence of treatment-emergent adverse events
Incidence of treatment-emergent adverse events
Time frame: Up to 104 weeks
Dose-limiting toxicities (DLTs)
Dose-limiting toxicities (DLTs)
Time frame: Through Day 28 post-first dose
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic→
RiboX Therapeutics Ltd.